Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to three new employees hired in August 2024. The awards include non-qualified stock options to purchase a total of 30,600 shares of Adicet's common stock at an exercise price of $1.46 per share.
The vesting schedule for these options is structured as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), un'azienda biotecnologica in fase clinica focalizzata sulle terapie con cellule T gamma delta allogeniche, ha concesso premi di indennità a tre nuovi dipendenti assunti nell'agosto 2024. I premi includono opzioni su azioni non qualificate per acquistare un totale di 30.600 azioni delle azioni ordinarie di Adicet a un prezzo di esercizio di $1,46 per azione.
Il programma di maturazione di queste opzioni è strutturato come segue: il 25% delle azioni maturerà al primo anniversario della data di inizio di ciascun ricevente, con il restante 75% che matura in 36 rate mensili successive. La maturazione completa avverrà al quarto anniversario della data di inizio del ricevente, a condizione di un'occupazione continuativa.
Questi premi sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti di Adicet, nell'ambito del Piano di Indennità 2022 dell'azienda, in conformità con la Regola di Quotazione 5635(c)(4) di Nasdaq.
Adicet Bio (Nasdaq: ACET), una empresa de biotecnología en etapa clínica centrada en terapias con células T gamma delta alogénicas, ha otorgado premios de incentivo a tres nuevos empleados contratados en agosto de 2024. Los premios incluyen opciones de acciones no calificadas para comprar un total de 30,600 acciones de las acciones ordinarias de Adicet a un precio de ejercicio de $1.46 por acción.
El calendario de adquisición de estas opciones está estructurado de la siguiente manera: el 25% de las acciones se adquirirán en el primer aniversario de la fecha de inicio de cada destinatario, con el 75% restante adquiriéndose en 36 pagos mensuales posteriores. La adquisición completa ocurrirá en el cuarto aniversario de la fecha de inicio del destinatario, sujeto a la continuación del empleo.
Estos premios se otorgaron fuera de los planes de incentivos patrimoniales aprobados por los accionistas de Adicet, bajo el Plan de Inducción 2022 de la compañía, en cumplimiento con la Regla de Cotización 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET)는 동종의 감마 델타 T 세포 치료에 초점을 맞춘 임상 단계의 생명공학 회사로, 2024년 8월에 채용된 신규 직원 3명에게 유인 보상을 부여했습니다. 보상에는 Adicet의 일반 주식 30,600주를 $1.46 per share의 행사가로 구매할 수 있는 비자격 주식 옵션이 포함되어 있습니다.
이 옵션의 일정은 다음과 같이 구성되어 있습니다: 각 수령인의 고용 시작일 1주년 기념일에 25%의 주식이 확정되며, 나머지 75%는 이후 36개월에 걸쳐 분할 확정됩니다. 모든 주식의 확정은 수령인의 시작일로부터 4주년째에 이루어지며, 이는 지속적인 고용에 따라 다릅니다.
이 보상은 Adicet의 주주 승인 자본 인센티브 계획 외부에서 부여되었으며, 회사의 2022 유인 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Adicet Bio (Nasdaq: ACET), une entreprise de biotechnologie en phase clinique axée sur les thérapies par cellules T gamma delta allogéniques, a accordé des primes d'induction à trois nouveaux employés embauchés en août 2024. Les primes comprennent des options d'achat d'actions non qualifiées pour acquérir un total de 30 600 actions d'Adicet à un prix d'exercice de 1,46 $ par action.
Le calendrier d'acquisition de ces options est structuré comme suit : 25 % des actions seront acquises à l'anniversaire d'un an de la date de début de chaque bénéficiaire, les 75 % restants seront acquis par tranches mensuelles de 36 mois par la suite. L'acquisition complète se produira au quatrième anniversaire de la date de début du bénéficiaire, sous réserve d'un maintien de l'emploi.
Ces récompenses ont été accordées en dehors des plans d'incitation au capital approuvés par les actionnaires d'Adicet, dans le cadre du Plan d'Induction 2022 de l'entreprise, conformément à la Règle de cotation 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf allogene Gamma-Delta-T-Zelltherapien konzentriert, hat Incentive Awards an drei neue Mitarbeiter vergeben, die im August 2024 eingestellt wurden. Diese Awards umfassen nicht qualifizierte Aktienoptionen zum Kauf von insgesamt 30.600 Aktien des Stammkapitals von Adicet zu einem Ausübungspreis von $1,46 pro Aktie.
Der Vesting-Zeitplan für diese Optionen liegt wie folgt: 25% der Aktien werden am ersten Jahrestag des Arbeitsbeginns jedes Empfängers fällig, die verbleibenden 75% werden dann in 36 monatlichen Raten fällig. Die vollständige Vesting erfolgt am vierten Jahrestag des Arbeitsbeginns des Empfängers, vorausgesetzt, die Beschäftigung bleibt bestehen.
Diese Awards wurden außerhalb der von den Aktionären von Adicet genehmigten Eigenkapitalanreizpläne im Rahmen des Unternehmensplans von 2022 für Anreize gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- Adicet Bio is attracting new talent, hiring three employees in August 2024
- The company has an Inducement Plan in place to offer competitive stock options to new hires
- The stock price of $1.46 per share indicates a relatively low valuation for the company
- The need for inducement grants may suggest challenges in attracting talent through standard compensation packages
Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 30,600 shares of Adicet’s common stock with an exercise price of
All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240830569475/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
How many shares of Adicet Bio (ACET) stock were granted as inducement awards in August 2024?
What was the exercise price for the stock options granted by Adicet Bio (ACET) on August 30, 2024?
What is the vesting schedule for the inducement stock options granted by Adicet Bio (ACET)?
Under which plan were the inducement awards granted by Adicet Bio (ACET)?
